Actio Biosciences spun out the remaining portion of its genetics-driven pipeline into Setara Biosciences after Jazz Pharmaceuticals acquired Actio’s lead epilepsy program. Setara will pursue a rare disease pipeline anchored by a Charcot-Marie-Tooth disease medicine that Actio was developing when the transaction was completed. The new startup is receiving $90 million in backing to build its second act, with plans to develop the lead program and potentially expand into additional indications from the genetic platform Actio built. This structure reflects a common pattern in rare-disease investing: monetizing one asset while preserving the remainder of the platform for re-development under a new corporate entity. The move matters for biotech strategy because it keeps development momentum alive while isolating risk and capital needs in a focused company profile.